Zuric 40 Tablet contains Febuxostat 40 mg, a xanthine oxidase inhibitor indicated for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout flares and the formation of urate crystals in joints and tissues. Zuric 40 is prescribed for patients who are intolerant to or inadequately controlled by allopurinol therapy. The tablet is administered orally, typically once daily, with or without food, as directed by a healthcare professional. It is important to monitor serum uric acid levels regularly during treatment to assess therapeutic efficacy and adjust dosage accordingly. Common adverse effects may include liver function abnormalities, nausea, rash, and joint pain. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in those with a known hypersensitivity to Febuxostat. Zuric 40 should be used under medical supervision, with attention to potential drug interactions, particularly with azathioprine and mercaptopurine. Proper adherence to prescribed dosing enhances treatment outcomes and reduces the risk of gout complications.